Brazilian researchers said on Wednesday the Covid-19 vaccine developed by China's Sinovac Biotech is more than 50 percent effective based on trial data, but again withheld full results at the company's request, raising questions about transparency.

Brazil is the first country to complete a late-stage trial of the vaccine, called CoronaVac, but a release of the results, first set for early December, has now been delayed three times...